KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) Short-Term Debt repayments (2012 - 2014)

AbbVie (ABBV) reported Short-Term Debt repayments of -$45.0 million for Q3 2014, up 18.18% year-over-year from -$38.1 million in Q3 2013, and down 125.0% on a QoQ basis from -$20.0 million in Q4 2013.

AbbVie (ABBV) has 3 years of Short-Term Debt repayments data on file, last reported at -$45.0 million in Q3 2014.

  • Quarterly Short-Term Debt repayments rose 18.18% year-over-year to -$45.0 million in Q3 2014, while the trailing twelve-month figure through Sep 2014 was -$50.0 million (up 99.62% YoY) and the FY2013 annual result came in at -$247.0 million, up 98.17% from the prior year.
  • Short-Term Debt repayments eased to -$45.0 million in Q3 2014 per ABBV's latest filing, from -$20.0 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $2.2 billion in Q3 2012 and bottomed at -$13.1 billion in Q4 2012.
  • The 3-year median for Short-Term Debt repayments is -$55.0 million (2013), against an average of -$1.5 billion.
  • Peak annual rise in Short-Term Debt repayments reached 105.28% in 2013, while the deepest fall reached 102.45% in 2013.
  • Tracing ABBV's Short-Term Debt repayments over 3 years: stood at -$13.1 billion in 2012, then surged by 99.85% to -$20.0 million in 2013, then plunged by 125.0% to -$45.0 million in 2014.
  • Per Business Quant, the three latest ABBV Short-Term Debt repayments figures stand at -$45.0 million (Q3 2014), -$20.0 million (Q4 2013), and -$55.0 million (Q3 2013).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -73.00 Mn
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 3.22 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2014 -45.00 Mn
Sep 30, 2014 -45.00 Mn
Dec 31, 2013 -20.00 Mn
Dec 31, 2013 -20.00 Mn
Sep 30, 2013 -55.00 Mn
Sep 30, 2013 -55.00 Mn
Jun 30, 2013 70.00 Mn
Jun 30, 2013 70.00 Mn
Mar 31, 2013 -242.00 Mn
Mar 31, 2013 -242.00 Mn
Dec 31, 2012 -13.06 Bn
Dec 31, 2012 -13.06 Bn
Sep 30, 2012 2.25 Bn
Sep 30, 2012 2.25 Bn
Jun 30, 2012 -1.33 Bn
Jun 30, 2012 -1.33 Bn
Mar 31, 2012 -1.37 Bn
Mar 31, 2012 -1.37 Bn